AAV-based in vivo mosaic screening platform
preclinicalplatform · high · Thu Feb 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Deliver and evaluate many genetic perturbations directly in diseased tissue environments across species and organs.
Modality-agnostic AAV delivery of knockouts, gain-of-function constructs, and synthetic miRNA knockdowns, analyzed with single-cell transcriptomics against human disease molecular signatures.
2026 bioRxiv preprint reported scalable screening across murine pulmonary fibrosis and aged horse osteoarthritis models.
Identified metabolic, antifibrotic, and immunomodulatory targets and showed prediction of outcomes in human ex vivo lung and cartilage models.
In vivo drug discovery platform
preclinicalplatform · high · Thu Feb 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify therapeutic targets and therapies for complex age-related diseases that are more likely to translate to human trials.
Proprietary in vivo drug discovery using Patient Avatars, Mosaic Screening, and Pythia transcriptome analysis.
Platform described publicly on company site and applied in 2026 multispecies AAV in vivo mosaic screening publication.
The platform ranked targets across biological domains and predicted functional outcomes in human ex vivo tissue models.
Osteoarthritis target discovery program
preclinicalresearch program · high · Thu Feb 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify interventions with therapeutic potential for osteoarthritis in aged, spontaneously diseased joints.
AAV-based in vivo mosaic screening in spontaneously osteoarthritic joints of aged horses, with transcriptomic scoring against human disease signatures and ex vivo cartilage validation.
2026 preprint reported aged horse osteoarthritis screening and human cartilage model validation.
The platform identified therapeutic target classes and predicted glycosaminoglycan restoration in cartilage.
Pulmonary fibrosis target discovery program
preclinicalresearch program · high · Thu Feb 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Discover and prioritize therapeutic targets for pulmonary fibrosis using in vivo functional genomics and human disease signatures.
Loss- and gain-of-function AAV mosaic screens in a murine pulmonary fibrosis model, followed by transcriptomic scoring and validation in human lung slice models.
2026 preprint reported pulmonary fibrosis screening results and human ex vivo collagen-reduction prediction.
The screen identified metabolic, antifibrotic, and immunomodulatory targets; analysis predicted soluble collagen reduction in human lung slices.
Viral delivery vehicle selection
exploratoryplatform · medium · Thu Nov 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Select and characterize viral delivery vehicles by identifying which cell types are transduced and how transduction is distributed across cells in tissue contexts.
Patent-described methods for viral delivery vehicle selection, with Gordian Biotechnology Inc. listed as assignee and Martin Borch Jensen and Daniel Fuentes as inventors.
WO2021231305A2 published on 2021-11-18.
Ferret bleomycin-induced lung injury model
preclinicalresearch program · medium
Develop a pulmonary fibrosis model that better reproduces human idiopathic pulmonary fibrosis features for therapeutic research.
Bleomycin-induced pulmonary fibrosis in ferrets, with pulmonary compliance, imaging, and single-nucleus RNA sequencing analyses.
2025 publication reported that the ferret model shares pathophysiological and molecular features of human IPF.
The model showed irreversible loss of pulmonary compliance, increased opacification, honeycomb-like structures, and epithelial shifts resembling human IPF.
WT1 pulmonary fibrosis target program
preclinicaldrug program · medium
Evaluate WT1 as a therapeutic target to reduce fibroblast accumulation and extracellular matrix production in idiopathic pulmonary fibrosis.
Single-nucleus RNA sequencing of IPF and control distal lung tissues plus WT1 loss- and gain-of-function studies in fibroblasts and bleomycin-induced pulmonary fibrosis models.
2025 Journal of Clinical Investigation publication identified WT1 as a regulator of prosurvival and ECM genes in IPF fibroblasts.
WT1 was selectively upregulated in IPF fibroblast subsets; fibroblast-specific WT1 overexpression worsened fibroproliferation, myofibroblast accumulation, and ECM production, supporting WT1 targeting as a strategy.
